Cargando…

Safety and Tolerability of Intravitreal Carotuximab (DE-122) in Patients With Persistent Exudative Age-Related Macular Degeneration: A Phase I Study

PURPOSE: Carotuximab (DE-122) is a novel endoglin antibody that exhibits potent anti-angiogenic activity. The aim of this study was to evaluate the safety and tolerability of a single intravitreal injection of four ascending doses of carotuximab in patients with persistent exudative age-related macu...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gonzalez, Victor H., Berger, Brian, Goldberg, Roger, Gordon, Carmelina M., Khurana, Rahul N., Angeles, Raymund, Shams, Naveed
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Association for Research in Vision and Ophthalmology 2021
Materias:	Clinical Trials
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8711001/ https://www.ncbi.nlm.nih.gov/pubmed/34935908 http://dx.doi.org/10.1167/tvst.10.14.27

Ejemplares similares

Intravitreal sirolimus for persistent, exudative age-related macular degeneration: a Pilot Study
por: Minturn, Robert J., et al.
Publicado: (2021)

Intravitreal Aflibercept Outcomes in Patients with Persistent Macular Exudate Previously Treated with Bevacizumab and/or Ranibizumab for Neovascular Age-Related Macular Degeneration
por: Griffin, David R., et al.
Publicado: (2014)

A phase I/II study of preoperative letrozole, everolimus, and carotuximab in stage 2 and 3 hormone receptor-positive and Her2-negative breast cancer
por: Vaklavas, Christos, et al.
Publicado: (2023)

Intravitreal aflibercept treatment in eyes with exudative age-related macular degeneration following prior treatment with intravitreal ranibizumab
por: Narayan, Daniel Sanju, et al.
Publicado: (2015)

Combined treatment of exudative age related macular degeneration with photodynamic therapy and intravitreal triamcinolone
por: Ruiz-Moreno, José Mª, et al.
Publicado: (2008)

Visual outcome of intravitreal ranibizumab for exudative age-related macular degeneration: timing and prognosis
por: Canan, Handan, et al.
Publicado: (2014)

Intravitreal sirolimus with adjunct aflibercept versus aflibercept monotherapy for persistent, exudative age-related macular degeneration: a pilot study
por: Rowe, Lucas W., et al.
Publicado: (2023)

Concomitant bilateral intravitreal anti-VEGF injections for the treatment of exudative age-related macular degeneration
por: Davis, R Prince, et al.
Publicado: (2010)

Intravitreal treatment in patients with exudative age-related macular degeneration and visual acuity ≤ 0.05
por: Koch, Raphael, et al.
Publicado: (2015)

The effect of vitreomacular adhesion in exudative age-related macular degeneration on the results of ranibizumab intravitreal injection
por: Suzuki, Hiroyuki, et al.
Publicado: (2017)

CLINICAL AND ELECTROPHYSIOLOGICAL EVALUATION AFTER INTRAVITREAL ZIV-AFLIBERCEPT FOR EXUDATIVE AGE-RELATED MACULAR DEGENERATION
por: de Oliveira Dias, João Rafael, et al.
Publicado: (2017)

Are Dilated Fundus Examinations Needed for OCT-Guided Retreatment of Exudative Age-Related Macular Degeneration? A Prospective, Randomized, Pilot Study
por: Solomon, Sharon D, et al.
Publicado: (2021)

Retinal pigment epithelial tears after intravitreal bevacizumab injection for exudative age-related macular degeneration
por: Shaikh, Saad, et al.
Publicado: (2007)

One-Year Results of Photodynamic Therapy Combined with Intravitreal Ranibizumab for Exudative Age-Related Macular Degeneration
por: Nakamura, Tomoko, et al.
Publicado: (2012)

Effectiveness of ranibizumab intravitreal injections for exudative age-related macular degeneration treatment: 12-month outcomes
por: Figurska, Małgorzata, et al.
Publicado: (2011)

Retinal pigment epithelial tear after intravitreal bevacizumab injection for exudative age-related macular degeneration
por: Singh, Sunil Kumar, et al.
Publicado: (2014)

AFLIBERCEPT AFTER RANIBIZUMAB INTRAVITREAL INJECTIONS IN EXUDATIVE AGE–RELATED MACULAR DEGENERATION: The ARI2 Study
por: Blanco-Garavito, Rocio, et al.
Publicado: (2018)

Effect of intravitreal bevacizumab on diabetic macular edema with hard exudates
por: Jeon, Sohee, et al.
Publicado: (2014)

Impact of Prophylactic Ranibizumab to Prevent Neovascular Age-Related Macular Degeneration on Eyes With Intermediate Age-Related Macular Degeneration
por: Chan, Clement K., et al.
Publicado: (2023)

Ganglion Cell Complex Evaluation in Exudative Age-Related Macular Degeneration after Repeated Intravitreal Injections of Ranibizumab
por: Perdicchi, Andrea, et al.
Publicado: (2015)

Intravitreal use of bone marrow mononuclear fraction containing CD34(+) stem cells in patients with atrophic age-related macular degeneration
por: Cotrim, Carina Costa, et al.
Publicado: (2017)

One-year outcomes of fixed treatment of intravitreal aflibercept for exudative age-related macular degeneration and the factor of visual prognosis
por: Ono, Aoi, et al.
Publicado: (2018)

One-year outcome of intravitreal aflibercept injection for age-related macular degeneration resistant to ranibizumab: rapid morphologic recovery and subsequent visual improvement
por: Hirakata, Toshiaki, et al.
Publicado: (2016)

Effect of Switching Therapy to Pegaptanib in Eyes With the Persistent Cases of Exudative Age-Related Macular Degeneration
por: Shiragami, Chieko, et al.
Publicado: (2014)

Intravitreal ziv-aflibercept for macular edema following retinal vein occlusion
por: Paulose, Remya, et al.
Publicado: (2016)

Therapeutic Modalities of Exudative Age-related Macular Degeneration
por: Mavija, Milka, et al.
Publicado: (2014)

Use of nepafenac (Nevanac(®)) in combination with intravitreal anti-VEGF agents in the treatment of recalcitrant exudative macular degeneration requiring monthly injections
por: Chen, Eric, et al.
Publicado: (2010)

Intravitreal aflibercept for exudative age-related macular degeneration with good visual acuity: 2-year results of a prospective study
por: Sakamoto, Shinichi, et al.
Publicado: (2018)

Prospective Study of Vessel Density by Optical Coherence Tomography Angiography After Intravitreal Bevacizumab in Exudative Age-Related Macular Degeneration
por: Cennamo, Gilda, et al.
Publicado: (2019)

Impact of Modifying Abicipar Manufacturing Process in Patients with Neovascular Age-Related Macular Degeneration: MAPLE Study Results
por: Callanan, David, et al.
Publicado: (2023)

Title: efficacy of intravitreal dexamethasone implant on hard exudate in diabetic macular edema
por: Yoon, Chang Ki, et al.
Publicado: (2021)

Lucentis(®) using Visudyne(®) study: determining the threshold-dose fluence of verteporfin photodynamic therapy combined with intravitreal ranibizumab for exudative macular degeneration
por: Chen, Eric, et al.
Publicado: (2010)

Intravitreal Anti-vascular Endothelial Growth Factor for Typical Exudative Age-related Macular Degeneration in Eyes with Good Baseline Visual Acuity
por: Chang, Young Suk, et al.
Publicado: (2014)

Clinical outcomes of 1 + PRN and 3 + Q3M regimens of intravitreal conbercept injection for exudative age-related macular degeneration
por: Gao, Lei, et al.
Publicado: (2020)

A Treat-and-Extend Regimen of Intravitreal Brolucizumab for Exudative Age-Related Macular Degeneration Refractory to Aflibercept: A 12-Month Result
por: Kikushima, Wataru, et al.
Publicado: (2023)

Short-term Efficacy and Safety of Intravitreal Brolucizumab Injection for Treatment-Naive Exudate Age-related Macular Degeneration: A Multicenter Study
por: Kim, Juno, et al.
Publicado: (2023)

Early Signs of Exudative Age-Related Macular Degeneration in Asians
por: Sasaki, Mariko, et al.
Publicado: (2014)

Treatment of Exudative Age-related Macular Degeneration: Focus on Aflibercept
por: García-Layana, Alfredo, et al.
Publicado: (2015)

Unusual visual loss in a patient with exudative macular degeneration
por: Peng, Enoch T., et al.
Publicado: (2022)

Functional Outcomes of the Low Vision Depression Prevention Trial in Age-Related Macular Degeneration
por: Deemer, Ashley D., et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_75no8liqo12mnuqf7anrvh9mfn